NCT06307925View on ClinicalTrials.gov

A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

122

Participants

Timeline

Start Date

March 27, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Advanced Solid Tumor

Interventions

DRUG

HC010

HC010 Q2W/28d intravenous infusion

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

Sponsors

Lead Sponsor

HC Biopharma Inc.

All Listed Sponsors

lead

HC Biopharma Inc.

INDUSTRY